CRP and non-small cell lung carcinoma: In a retrospective cohort study including 124 NSCLC patients treated with the PD-1 inhibitor nivolumab Oya et al. identified elevated CRP levels above the upper limit of normal (≥1.0 mg/dL = 10 mg/L) as an independent predictor of decreased PFS, whereas for OS and ORR analysis only a univariate model was performed [29].